Current and historical daily PE Ratio for Dr Reddy's Laboratories Ltd (
FRA:RDDA
) from 1990 to May 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Dr Reddy's Laboratories stock (FRA:RDDA) PE ratio as of May 22 2024 is 17.49.
More Details
Dr Reddy's Laboratories Ltd (FRA:RDDA) PE Ratio (TTM) Chart
Dr Reddy's Laboratories Ltd (FRA:RDDA) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1250
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Dr Reddy's Laboratories PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-22 | 16.8 | 2024-03-15 | 19.5 |
| 2024-05-21 | 16.8 | 2024-03-14 | 19.4 |
| 2024-05-20 | 16.6 | 2024-03-13 | 19.6 |
| 2024-05-17 | 16.9 | 2024-03-12 | 19.9 |
| 2024-05-16 | 16.9 | 2024-03-11 | 20.2 |
| 2024-05-15 | 17.3 | 2024-03-08 | 19.6 |
| 2024-05-14 | 17.0 | 2024-03-07 | 20.1 |
| 2024-05-13 | 17.2 | 2024-03-06 | 19.9 |
| 2024-05-10 | 17.2 | 2024-03-05 | 20.4 |
| 2024-05-09 | 17.4 | 2024-03-04 | 19.8 |
| 2024-05-08 | 17.7 | 2024-03-01 | 19.8 |
| 2024-05-07 | 18.5 | 2024-02-29 | 20.4 |
| 2024-05-06 | 18.8 | 2024-02-28 | 20.5 |
| 2024-05-03 | 18.5 | 2024-02-27 | 20.4 |
| 2024-05-02 | 18.4 | 2024-02-26 | 20.1 |
| 2024-04-30 | 18.4 | 2024-02-23 | 20.5 |
| 2024-04-29 | 18.4 | 2024-02-22 | 19.8 |
| 2024-04-26 | 18.4 | 2024-02-21 | 20.4 |
| 2024-04-25 | 17.7 | 2024-02-20 | 19.6 |
| 2024-04-24 | 17.7 | 2024-02-19 | 19.6 |
| 2024-04-23 | 18.1 | 2024-02-16 | 19.6 |
| 2024-04-22 | 17.8 | 2024-02-15 | 19.8 |
| 2024-04-19 | 17.7 | 2024-02-14 | 19.6 |
| 2024-04-18 | 17.7 | 2024-02-13 | 19.6 |
| 2024-04-17 | 17.8 | 2024-02-12 | 19.4 |
| 2024-04-16 | 18.0 | 2024-02-09 | 19.4 |
| 2024-04-15 | 17.8 | 2024-02-08 | 19.1 |
| 2024-04-12 | 18.0 | 2024-02-07 | 19.1 |
| 2024-04-11 | 18.0 | 2024-02-06 | 19.5 |
| 2024-04-10 | 18.0 | 2024-02-05 | 18.8 |
| 2024-04-09 | 18.0 | 2024-02-02 | 18.8 |
| 2024-04-08 | 18.3 | 2024-02-01 | 18.8 |
| 2024-04-05 | 17.8 | 2024-01-31 | 19.4 |
| 2024-04-04 | 18.3 | 2024-01-30 | 18.2 |
| 2024-04-03 | 18.1 | 2024-01-29 | 17.9 |
| 2024-04-02 | 18.5 | 2024-01-26 | 18.1 |
| 2024-03-28 | 18.5 | 2024-01-25 | 18.1 |
| 2024-03-27 | 19.2 | 2024-01-24 | 18.2 |
| 2024-03-26 | 19.4 | 2024-01-23 | 17.6 |
| 2024-03-25 | 19.5 | 2024-01-22 | 18.1 |
| 2024-03-22 | 18.9 | 2024-01-19 | 17.5 |
| 2024-03-21 | 18.6 | 2024-01-18 | 17.4 |
| 2024-03-20 | 18.8 | 2024-01-17 | 17.9 |
| 2024-03-19 | 19.6 | 2024-01-16 | 18.4 |
| 2024-03-18 | 19.9 | 2024-01-12 | 17.8 |
Dr Reddy's Laboratories Ltd (FRA:RDDA) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Dr Reddy's Laboratories Ltd
NAICS : 325412
SIC : 2834
ISIN : US2561352038
Share Class Description:
FRA:RDDA: ADRDescription
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers